(Q39532576)

English

Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors

scientific article published on 8 August 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

0 references

oncolytic virus

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Akseli Hemminki

21

object named as

Akseli Hemminki

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

19

object named as

Timo Joensuu

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

14

object named as

Minna Oksanen

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

2

object named as

Iulia Diaconu

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Sophie Escutenaire

4

object named as

Sophie Escutenaire

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

20

object named as

Anna Kanerva

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

1

object named as

Sari Pesonen

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Lotta Kangasniemi

6

object named as

Lotta Kangasniemi

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

10

object named as

Leena Laasonen

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

author name string

Vincenzo Cerullo

3

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Mari Raki

5

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Petri Nokisalmi

7

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Gianpietro Dotti

8

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Kilian Guse

9

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Kaarina Partanen

11

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Eerika Karli

12

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Elina Haavisto

13

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Aila Karioja-Kallio

15

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Päivi Hannuksela

16

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Sirkka-Liisa Holm

17

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Satu Kauppinen

18

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

language of work or name

0 references

publication date

8 August 2011

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

number of pages

11

1 reference

based on heuristic

inferred from page(s)

International Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

130

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

1937-1947

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

A smart move against cancer for vaccinia virus

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26216

21 January 2018

In situ adenovirus vaccination engages T effector cells against cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26216

21 January 2018

Activation of tumor-specific CD8+ T Cells after intratumoral Ad5-TRAIL/CpG oligodeoxynucleotide combination therapy.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26216

21 January 2018

Dendritic cells and the control of immunity

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26216

21 January 2018

Evidence that granulocyte macrophage-colony-stimulating factor regulates the distribution and differentiated state of dendritic cells/Langerhans cells in human lung and lung cancers

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26216

21 January 2018

Intralesional granulocyte-monocyte colony-stimulating factor followed by subcutaneous interleukin-2 in metastatic melanoma: a pilot study in elderly patients

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26216

21 January 2018

A Phase I study of KH901, a conditionally replicating granulocyte-macrophage colony-stimulating factor: armed oncolytic adenovirus for the treatment of head and neck cancers.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26216

21 January 2018

A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26216

21 January 2018

Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26216

21 January 2018

A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26216

21 January 2018

A cyclooxygenase-2 promoter-based conditionally replicating adenovirus with enhanced infectivity for treatment of ovarian adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26216

21 January 2018

Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26216

21 January 2018

A modified E2F-1 promoter improves the efficacy to toxicity ratio of oncolytic adenoviruses.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26216

21 January 2018

Evaluation of a selectively oncolytic adenovirus for local and systemic treatment of cervical cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26216

21 January 2018

Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26216

21 January 2018

Comparison of one-, two-, and three-dimensional measurements of childhood brain tumors

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26216

21 January 2018

Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26216

21 January 2018

Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with metastatic and refractory solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26216

21 January 2018

Noninvasive imaging for evaluation of the systemic delivery of capsid-modified adenoviruses in an orthotopic model of advanced lung cancer.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26216

21 January 2018

Systemic efficacy of oncolytic adenoviruses in imagable orthotopic models of hormone refractory metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26216

21 January 2018

Regulation of myeloid development and function by colony stimulating factors.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26216

21 January 2018

Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26216

21 January 2018

Adenovirus hexon T-cell epitope is recognized by most adults and is restricted by HLA DP4, the most common class II allele

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26216

21 January 2018

Enhanced oncolysis by a tropism-modified telomerase-specific replication-selective adenoviral agent OBP-405 ('Telomelysin-RGD').

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26216

21 January 2018

Coxsackievirus and adenovirus receptor expression on primary osteosarcoma specimens and implications for gene therapy with recombinant adenoviruses.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26216

21 January 2018

E1A, E1B double-restricted adenovirus with RGD-fiber modification exhibits enhanced oncolysis for CAR-deficient biliary cancers

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26216

21 January 2018

Current developments in adenovirus-based cancer gene therapy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26216

21 January 2018

Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26216

21 January 2018

Treatment of metastatic neuroblastoma with systemic oncolytic virotherapy delivered by autologous mesenchymal stem cells: an exploratory study.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26216

21 January 2018

Oncolytic adenovirus treatment of a patient with refractory neuroblastoma

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26216

21 January 2018

Stimulation of suppressor cells in the bone marrow and spleens of high dose cyclophosphamide-treated C57Bl/6 mice.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26216

21 January 2018

Linked tumor-selective virus replication and transgene expression from E3-containing oncolytic adenoviruses

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26216

21 January 2018

Regulatory T cells, tumour immunity and immunotherapy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26216

21 January 2018

Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26216

21 January 2018

Identifiers

10.1002/IJC.26216

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39532576&oldid=1836146527"